Tressa Hood

613 total citations
20 papers, 133 citations indexed

About

Tressa Hood is a scholar working on Oncology, Hematology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Tressa Hood has authored 20 papers receiving a total of 133 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 7 papers in Hematology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Tressa Hood's work include Acute Myeloid Leukemia Research (6 papers), CAR-T cell therapy research (3 papers) and Chronic Myeloid Leukemia Treatments (3 papers). Tressa Hood is often cited by papers focused on Acute Myeloid Leukemia Research (6 papers), CAR-T cell therapy research (3 papers) and Chronic Myeloid Leukemia Treatments (3 papers). Tressa Hood collaborates with scholars based in United States, United Kingdom and Germany. Tressa Hood's co-authors include Sean Ferree, Anne‐Vibeke Lænkholm, Maj‐Britt Jensen, Bent Ejlertsen, Torsten O. Nielsen, Wesley Buckingham, Jens Ole Eriksen, Alan Jackson, Patrick Danaher and Sarah Warren and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Tressa Hood

19 papers receiving 132 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tressa Hood United States	8	71	43	37	32	25	20	133
Sumito Shingaki Japan	4	35 0.5×	33 0.8×	87 2.4×	24 0.8×	8 0.3×	15	134
Donata Sartori Italy	6	72 1.0×	51 1.2×	22 0.6×	36 1.1×	5 0.2×	18	126
Mohammad Atiq United States	6	88 1.2×	26 0.6×	54 1.5×	64 2.0×	49 2.0×	21	155
Tetsuhiro Yoshinami Japan	6	116 1.6×	50 1.2×	33 0.9×	53 1.7×	5 0.2×	48	174
Marcin M. Machnicki Poland	8	36 0.5×	16 0.4×	55 1.5×	13 0.4×	22 0.9×	25	142
Manuel Torres-Diz Spain	6	75 1.1×	49 1.1×	158 4.3×	32 1.0×	29 1.2×	11	218
Spencer H. Shao United States	8	116 1.6×	41 1.0×	26 0.7×	22 0.7×	16 0.6×	13	167
Rohit Thummalapalli United States	8	94 1.3×	41 1.0×	78 2.1×	56 1.8×	52 2.1×	17	192
I. Meuthen Germany	5	63 0.9×	19 0.4×	19 0.5×	18 0.6×	16 0.6×	11	126
Pingyong Yi China	9	75 1.1×	18 0.4×	40 1.1×	20 0.6×	35 1.4×	14	149

Countries citing papers authored by Tressa Hood

Since Specialization

Citations

This map shows the geographic impact of Tressa Hood's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tressa Hood with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tressa Hood more than expected).

Fields of papers citing papers by Tressa Hood

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tressa Hood. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tressa Hood. The network helps show where Tressa Hood may publish in the future.

Co-authorship network of co-authors of Tressa Hood

This figure shows the co-authorship network connecting the top 25 collaborators of Tressa Hood. A scholar is included among the top collaborators of Tressa Hood based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tressa Hood. Tressa Hood is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hanna, Glenn J., Gregory M. Coté, Rashmi Chugh, et al.. (2025). Safety and Efficacy of a Selective Inhibitor of Cyclin-dependent Kinase 9 (KB-0742) in Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma. Cancer Research Communications. 5(5). 767–773.

Villalona‐Calero, Miguel A., Glenn J. Hanna, Mark Agulnik, et al.. (2024). Study update of the oral CDK9 inhibitor KB-0742 in relapsed or refractory transcriptionally addicted advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). 3102–3102. 7 indexed citations

Carvajal, Luis A., et al.. (2023). The Combination of Lanraplenib, a Selective SYK Inhibitor, and Gilteritinib, a FLT3 Inhibitor, Targets Aberrant Proliferation and Differentiation Blockade in Acute Myeloid Leukemia. Blood. 142(Supplement 1). 5951–5951. 2 indexed citations

Carvajal, Luis A., Andrew S. Boghossian, Matthew G. Rees, et al.. (2023). The Novel Profiling Relative Inhibition Simultaneously in Mixtures (PRISM) Platform Identifies Synergistic Activity of Lanraplenib and Ruxolitinib in Hematological Malignancies. Blood. 142(Supplement 1). 2259–2259. 1 indexed citations

Saffran, Douglas C., Tressa Hood, Nikolaus D. Obholzer, et al.. (2022). Abstract 2564: CDK9 inhibition via KB-0742 is a potential strategy to treat transcriptionally addicted cancers. Cancer Research. 82(12_Supplement). 2564–2564. 3 indexed citations

Saffran, Douglas C., Tressa Hood, Nikolaus D. Obholzer, et al.. (2022). Abstract 2565: CDK9 inhibitor KB-0742 is active in preclinical models of small-cell lung cancer. Cancer Research. 82(12_Supplement). 2565–2565. 1 indexed citations

Carvajal, Luis A., Mick McKeown, Tressa Hood, et al.. (2022). SYK Inhibitors, Entospletinib and Lanraplenib, Show Potent Anti-Leukemic Activity in Combination with Targeted Agents. Blood. 140(Supplement 1). 5932–5933. 2 indexed citations

Saffran, Douglas C., Nathalie Rioux, Tom Chen, et al.. (2022). Abstract P5-08-05: Preclinical activity of KB-0742, an oral, highly selective, CDK9 inhibitor, in cell lines and in MYC-high expressing, patient-derived models of multiple breast cancer subtypes. Cancer Research. 82(4_Supplement). P5–8. 3 indexed citations

Vadakekolathu, Jayakumar, Catherine Lai, Stephen Reeder, et al.. (2020). Abstract CT035: TP53 abnormalities correlate with immune infiltration and are associated with response to flotetuzumab, an investigational immunotherapy, in acute myeloid leukemia. Cancer Research. 80(16_Supplement). CT035–CT035. 1 indexed citations

10.

Sorenson, Laurie, Yanfen Fu, Tressa Hood, Sarah Warren, & Troy A. McEachron. (2019). Targeted transcriptional profiling of the tumor microenvironment reveals lymphocyte exclusion and vascular dysfunction in metastatic osteosarcoma. OncoImmunology. 8(9). e1629779–e1629779. 8 indexed citations

11.

Jensen, Maj‐Britt, Anne‐Vibeke Lænkholm, Torsten O. Nielsen, et al.. (2018). The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer. Breast Cancer Research. 20(1). 79–79. 43 indexed citations

12.

Rutella, Sergio, S. Church, Jayakumar Vadakekolathu, et al.. (2018). Adaptive Immune Gene Signatures Correlate with Response to Flotetuzumab, a CD123 × CD3 Bispecific Dart® Molecule, in Patients with Relapsed/Refractory Acute Myeloid Leukemia. Blood. 132(Supplement 1). 444–444. 11 indexed citations

13.

Rutella, Sergio, Jayakumar Vadakekolathu, Heidi Altmann, et al.. (2018). Capturing the complexity of the immune microenvironment of acute myeloid leukemia with 3D biology technology.. Journal of Clinical Oncology. 36(5_suppl). 50–50. 6 indexed citations

14.

Vadakekolathu, Jayakumar, Tasleema Patel, Stephen Reeder, et al.. (2017). Immune gene expression profiling in children and adults with acute myeloid leukemia identifies distinct phenotypic patterns. Blood. 130. 3942–3942. 9 indexed citations

15.

Wallden, Brett, Irena Pekker, Naeem Dowidar, et al.. (2016). Development and analytical performance of a molecular diagnostic for anti-PD1 response on the nCounter Dx Analysis System.. Journal of Clinical Oncology. 34(15_suppl). 3034–3034. 16 indexed citations

16.

Chen, Ning, Patrick Danaher, Brett Wallden, et al.. (2016). Analytical Validation of the nCounter®-based Lymphoma Subtyping Test (LST) for Cell-of-Origin (COO) Identification in Formalin-Fixed Paraffin-Embedded (FFPE) Diffuse Large B-Cell Lymphoma (DLBCL) Specimens. Blood. 128(22). 2933–2933. 2 indexed citations

17.

Storhoff, James J., Brett Wallden, Rita M. Braziel, et al.. (2015). Analytical Performance of Nanostring's Companion Diagnostic (CDx) Lymphoma Subtyping Test (LST) with Diffuse Large B-Cell Lymphoma Core Needle Biopsy Samples. Blood. 126(23). 1481–1481. 1 indexed citations

18.

Wallden, Brett, Sean Ferree, Harini Ravi, et al.. (2015). Development of the molecular diagnostic (MDx) DLBCL Lymphoma Subtyping Test (LST) on the nCounter Analysis System.. Journal of Clinical Oncology. 33(15_suppl). 8536–8536. 9 indexed citations

19.

Hood, Tressa. (1960). Reporting of Communicable Disease. New England Journal of Medicine. 263(16). 814–814. 1 indexed citations

20.

Jackson, Alan & Tressa Hood. (1958). SARCOIDOSIS WITH INVOLVEMENT OF THE PITUITARY GLAND. Annals of Internal Medicine. 49(2). 467–471. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact